Headache and Migraine

A Phase 1 study in healthy lactating women found that a single 10‑mg dose of zavegepant nasal spray was generally safe, well tolerated, and resulted in minimal infant exposure through breast milk.

Neurology News Network for the week ending January 10, 2025. [WATCH TIME: 4 minutes]

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Neurology News Network for the week ending December 27, 2025. [WATCH TIME: 4 minutes]

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

A new study confirms the Nerivio REN wearable provides long-term, drug-free migraine relief without dosage increases, ensuring consistent effectiveness over 3 years.

Despite not meeting its primary efficacy end point for preventive treatment of episodic migraine, onabotulinumtoxinA was well tolerated and safety outcomes were consistent with prior data.

A new study reveals that early treatment with the Nerivio wearable significantly enhances migraine relief, doubling efficacy outcomes for patients.

A physician assistant who specializes in neurology previewed her upcoming presentation on evaluating patients with headache at the 2025 Baptist Miami Neuroscience Symposium.

Salvia BioElectronics’ PRIMUS system, currently being assessed in a clinical trial, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.

In a recent randomized clinical trial, a smartphone-based relaxation technique provided to patients presenting to the emergency department was associated with reduced migraine-related disability.

At AHS 2025, Eric Baron, DO, headache specialist at Cleveland Clinic, presented findings from a cross-sectional survey that examined psychedelic use among Canadian patients with migraine and cluster headache.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of trigeminal neuralgia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 19, 2025.